<?xml version="1.0" encoding="UTF-8"?>
<p>After providing informed consent, the patient received 2 mg/kg nivolumab combined with approximately 5 Ã— 10
 <sup>9</sup> CIK cells every 3 weeks starting in April 2018. After two cycles of therapy, the patient experienced increased appetite, but a CT scan performed 2 months after initiation of this therapy revealed enlarged and new pulmonary metastases. We continued to apply nivolumab and CIK cells combination therapy. After 6 months of therapy, a CT showed that the lesions in the lungs had begun to decrease (
 <xref ref-type="fig" rid="f1">
  <bold>Figure 1</bold>
 </xref>). Subsequent CT scans showed progressive disease reduction until November 2019.
</p>
